Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients

Affiliations

Comment

Yun-Fan Liaw. J Hepatol. 2018 May.

. 2018 May;68(5):1102-1104.

doi: 10.1016/j.jhep.2017.12.031. Epub 2018 Feb 1.

¹ Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan. Electronic address: liveryfl@gmail.com.

No abstract available

Comment in

Reply to: "Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients".
Berg T, Petersen J; FINITE [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B] study authors. Berg T, et al. J Hepatol. 2018 May;68(5):1104-1105. doi: 10.1016/j.jhep.2018.01.018. Epub 2018 Feb 2. J Hepatol. 2018. PMID: 29409742 No abstract available.

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J; FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B]. Berg T, et al. J Hepatol. 2017 Nov;67(5):918-924. doi: 10.1016/j.jhep.2017.07.012. Epub 2017 Jul 21. J Hepatol. 2017. PMID: 28736139 Clinical Trial.